Your browser doesn't support javascript.
loading
Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors.
Cleary, James M; Wang, Victoria; Heist, Rebecca S; Kopetz, E Scott; Mitchell, Edith P; Zwiebel, James A; Kapner, Kevin S; Chen, Helen X; Li, Shuli; Gray, Robert J; McShane, Lisa M; Rubinstein, Larry V; Patton, David R; Meric-Bernstam, Funda; Dillmon, Melissa S; Williams, P Mickey; Hamilton, Stanley R; Conley, Barbara A; Aguirre, Andrew J; O'Dwyer, Peter J; Harris, Lyndsay N; Arteaga, Carlos L; Chen, Alice P; Flaherty, Keith T.
Afiliación
  • Cleary JM; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. jcleary@partners.org.
  • Wang V; Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Heist RS; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Kopetz ES; University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Mitchell EP; Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.
  • Zwiebel JA; Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland.
  • Kapner KS; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Chen HX; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland.
  • Li S; Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Gray RJ; Dana-Farber Cancer Institute, Boston, Massachusetts.
  • McShane LM; Biometric Research Program, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland.
  • Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland.
  • Patton DR; Center for Biomedical Informatics and Information Technology, NCI, Bethesda, Maryland.
  • Meric-Bernstam F; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Dillmon MS; Harbin Clinic Medical Oncology and Clinical Research. Rome, Georgia.
  • Williams PM; Frederick National Laboratory for Cancer Research, Frederick, Maryland.
  • Hamilton SR; University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Conley BA; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland.
  • Aguirre AJ; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • O'Dwyer PJ; University of Pennsylvania, Philadelphia, Pennsylvania.
  • Harris LN; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland.
  • Arteaga CL; UT Southwestern Medical Center, Dallas, Texas.
  • Chen AP; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland.
  • Flaherty KT; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Clin Cancer Res ; 27(11): 2996-3004, 2021 06 01.
Article en En | MEDLINE | ID: mdl-33637626
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Bencimidazoles / Codón / Neoplasias Colorrectales / Ameloblastoma / Neoplasias Maxilomandibulares / GTP Fosfohidrolasas / Proteínas de la Membrana / Mutación Tipo de estudio: Clinical_trials / Guideline Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Bencimidazoles / Codón / Neoplasias Colorrectales / Ameloblastoma / Neoplasias Maxilomandibulares / GTP Fosfohidrolasas / Proteínas de la Membrana / Mutación Tipo de estudio: Clinical_trials / Guideline Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article